AAAAAA
Results:
1-8
|
Results: 8
Authors:
Odin, L
Favrot, M
Poujol, D
Michot, JP
Moingeon, P
Tartaglia, J
Puisieux, I
Citation: L. Odin et al., Canarypox virus expressing wild type p53 for gene therapy in murine tumorsmutated in p53, CANC GENE T, 8(2), 2001, pp. 87-98
Authors:
Burdin, N
Moingeon, P
Citation: N. Burdin et P. Moingeon, Cancer vaccines based on dendritic cells loaded with tumor-associated antigens, CELL BIOL T, 17(2), 2001, pp. 67-75
Authors:
Moingeon, P
Citation: P. Moingeon, Therapeutic vaccines, BIOFUTUR, 2001(212), 2001, pp. 54-57
Authors:
Moingeon, P
Haensler, J
Lindberg, A
Citation: P. Moingeon et al., Towards the rational design of Th1 adjuvants, VACCINE, 19(31), 2001, pp. 4363-4372
Authors:
Tartaglia, J
Bonnet, MC
Berinstein, N
Barber, B
Klein, M
Moingeon, P
Citation: J. Tartaglia et al., Therapeutic vaccines against melanoma and colorectal cancer, VACCINE, 19(17-19), 2001, pp. 2571-2575
Authors:
Rosenwirth, B
Kuhn, EM
Heeney, JL
Hurpin, C
Tartaglia, J
Bonnet, MC
Moingeon, P
Erdile, L
Citation: B. Rosenwirth et al., Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques, VACCINE, 19(13-14), 2001, pp. 1661-1670
Authors:
Moingeon, P
Citation: P. Moingeon, Cancer vaccines, VACCINE, 19(11-12), 2001, pp. 1305-1326
Authors:
Bonnet, MC
Tartaglia, J
Verdier, F
Kourilsky, P
Lindberg, A
Klein, M
Moingeon, P
Citation: Mc. Bonnet et al., Recombinant viruses as a tool for therapeutic vaccination against human cancers, IMMUNOL LET, 74(1), 2000, pp. 11-25
Risultati:
1-8
|